Microbiotica Reports Positive Phase 1b Trial for MB097 with Pembrolizumab
Question
Microbiotica Reports Positive Phase 1b Trial for MB097 with Pembrolizumab
Direct answer
Microbiotica delivered Phase 1b clinical data from its MELODY-1 trial at the European Society for Medical Oncology (ESMO) Congress 2026. The study evaluated MB097, an investigational microbiome therapeutic, administered alongside Merck's PD-1 inhibitor pembrolizumab (Keytruda). The patient cohort consisted of advanced melanoma cases unresponsive to primary checkpoint inhibitor treatment. Findings confirmed safety clearance, bacterial engraftment, and measurable clinical response rates, providing evidence for microbiome co-therapies in refractory oncology settings. — bullish pressure on MRK.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-26
- Published
- 2026-10-28
- Revision
- 1 · 2026-10-29
Cite as: Market Ontology, “Microbiotica Reports Positive Phase 1b Trial for MB097 with Pembrolizumab”, revision 1, evidence through 2026-10-26. https://marketontology.com/catalysts/2026-10-26/microbiotica-reports-positive-phase-1b-trial-for-mb097-with-pembrolizumab-fa8c06
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| MRK | ▲Bull | 1–4 weeks | Policy Shift | 68 |
Microbiotica Reports Positive Phase 1b Trial for MB097 with Pembrolizumab
Microbiotica delivered Phase 1b clinical data from its MELODY-1 trial at the European Society for Medical Oncology (ESMO) Congress 2026. The study evaluated MB097, an investigational microbiome therapeutic, administered alongside Merck's PD-1 inhibitor pembrolizumab (Keytruda). The patient cohort consisted of advanced melanoma cases unresponsive to primary checkpoint inhibitor treatment. Findings confirmed safety clearance, bacterial engraftment, and measurable clinical response rates, providing evidence for microbiome co-therapies in refractory oncology settings. — bullish pressure on MRK.
Microbiotica delivered Phase 1b clinical data from its MELODY-1 trial at the European Society for Medical Oncology (ESMO) Congress 2026. The study evaluated MB097, an investigational microbiome therapeutic, administered alongside Merck's PD-1 inhibitor pembrolizumab (Keytruda). The patient cohort consisted of advanced melanoma cases unresponsive to primary checkpoint inhibitor treatment. Findings confirmed safety clearance, bacterial engraftment, and measurable clinical response rates, providing evidence for microbiome co-therapies in refractory oncology settings.
- SummaryMicrobiotica delivered Phase 1b clinical data from its MELODY-1 trial at the European Society for Medical Oncology (ESMO) Congress 2026. The study evaluated MB097, an investigational microbiome therapeutic, administered alongside Merck's PD-1 inhibitor pembrolizumab (Keytruda). The patient cohort consisted of advanced melanoma cases unresponsive to primary checkpoint inhibitor treatment. Findings confirmed safety clearance, bacterial engraftment, and measurable clinical response rates, providing evidence for microbiome co-therapies in refractory oncology settings.
- MRKDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- MRK closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- MRK price vs. pre-event level
- MRK volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| MRK | Bullishagreed | 140.61 2026-10-26 | +0.86% | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-26J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous AmivantamabJNJ MRK+0.86%
- 2026-10-26Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancerJNJ MRK+0.86%
- 2026-10-26J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous AmivantamabJNJ MRK+0.86%
- 2026-10-26Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancerJNJ MRK+0.86%
- 2026-10-26Microbiotica presents Phase 1b melanoma data combining MB097 with KeytrudaMRK+0.86%
- 2026-10-26Microbiotica presents Phase 1b melanoma data combining MB097 with KeytrudaMRK+0.86%
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ MRK+0.86%
- 2026-10-26J&J reports 77% response rate for subcutaneous amivantamab regimen in head and neck cancerJNJ MRK+0.86%
Find trades for this development
Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.
First 10 runs free
See today's live cards
Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.